INS and type 1 diabetes mellitus: From the 2009-2011 to 2021-2023 study periods, there was a substantial increase in the use of CGM (4% [95% CI, 3%-4%] to 82% [95% CI, 81%-83%]; P < .001 for trend) and insulin pumps (16% [95% CI, 15%-17%] to 50% [95% CI, 81%-83%]; P < .001 for trend) among youths with T1D (Figure 3A).